Understanding Neutropenia Secondary to Intrinsic or Iatrogenic Immune Dysregulation

Overview

Journal Hematology Am Soc Hematol Educ Program

Specialty Hematology

Date 2021 Dec 10

PMID 34889406

Citations 3

Authors

Kelly Walkovich

James A Connelly

Affiliations

Soon will be listed here.

Abstract

As a key member of the innate and adaptive immune response, neutrophils provide insights into the hematopoietic and inflammatory manifestations of inborn errors of immunity (IEI) and the consequences of immunotherapy. The facile recognition of IEI presenting with neutropenia provides an avenue for hematologists to facilitate early diagnosis and expedite biologically rationale care. Moreover, enhancing the understanding of the molecular mechanisms driving neutropenia in IEI-decreased bone marrow reserves, diminished egress from the bone marrow, and decreased survival-offers an opportunity to further dissect the pathophysiology driving neutropenia secondary to iatrogenic immune dysregulation, eg, immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.

Citing Articles

Chronic neutropenia in childhood: experience of a tertiary center.

Matushita L, Valera E, Aragon D, Scridelli C, Roxo-Junior P, de Carvalho L J Pediatr (Rio J). 2024; 100(3):311-317.

PMID: 38182128 PMC: 11065660. DOI: 10.1016/j.jped.2023.12.003.

Organ-based clues for diagnosis of inborn errors of immunity: A practical guide for clinicians.

Mohammadi F, Yadegar A, Mardani M, Ayati A, Abolhassani H, Rezaei N Immun Inflamm Dis. 2023; 11(4):e833.

PMID: 37102642 PMC: 10091206. DOI: 10.1002/iid3.833.

Peripheral-blood cytopenia, an early indicator of inborn errors of immunity.

Cornelissen H, Musekwa E, Glashoff R, Esser M, Zunza M, Abraham D Br J Haematol. 2022; 198(5):875-886.

PMID: 35791731 PMC: 9544345. DOI: 10.1111/bjh.18337.

References

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Seidel M . Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Blood. 2014; 124(15):2337-44. PMC: 4192747. DOI: 10.1182/blood-2014-06-583260. View

Solanilla A, Dechanet J, El Andaloussi A, Dupouy M, Godard F, Chabrol J . CD40-ligand stimulates myelopoiesis by regulating flt3-ligand and thrombopoietin production in bone marrow stromal cells. Blood. 2000; 95(12):3758-64. View

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D . Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019; 380(18):1726-1737. PMC: 8202968. DOI: 10.1056/NEJMoa1817226. View

Chakraborty R, Hill B, Majeed A, Majhail N . Late Effects after Chimeric Antigen Receptor T cell Therapy for Lymphoid Malignancies. Transplant Cell Ther. 2021; 27(3):222-229. PMC: 8078596. DOI: 10.1016/j.jtct.2020.10.002. View

Zhuang J, Du J, Guo X, Zhou J, Duan L, Qiu W . Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. Thorac Cancer. 2020; 11(3):799-804. PMC: 7049514. DOI: 10.1111/1759-7714.13281. View

Meyts I, Aksentijevich I . Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment. J Clin Immunol. 2018; 38(5):569-578. PMC: 6061100. DOI: 10.1007/s10875-018-0525-8. View

Pasquet M, Bellanne-Chantelot C, Tavitian S, Prade N, Beaupain B, Larochelle O . High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. Blood. 2012; 121(5):822-9. PMC: 3714670. DOI: 10.1182/blood-2012-08-447367. View

Davis E, Salem J, Young A, Green J, Ferrell P, Ancell K . Hematologic Complications of Immune Checkpoint Inhibitors. Oncologist. 2019; 24(5):584-588. PMC: 6516131. DOI: 10.1634/theoncologist.2018-0574. View

10.

Blume R, Bennett J, Yankee R, Wolff S . Defective granulocyte regulation in the Chediak-Higashi syndrome. N Engl J Med. 1968; 279(19):1009-15. DOI: 10.1056/NEJM196811072791901. View

11.

Dunleavy K, Hakim F, Kim H, Janik J, Grant N, Nakayama T . B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood. 2005; 106(3):795-802. PMC: 1895166. DOI: 10.1182/blood-2004-08-3198. View

12.

Spinner M, Sanchez L, Hsu A, Shaw P, Zerbe C, Calvo K . GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2013; 123(6):809-21. PMC: 3916876. DOI: 10.1182/blood-2013-07-515528. View

13.

Omar N, El-Fass K, Abushouk A, Elbaghdady N, Barakat A, Noreldin A . Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review. Front Immunol. 2020; 11:1354. PMC: 7640759. DOI: 10.3389/fimmu.2020.01354. View

14.

Jacobs Z, Guajardo J, Anderson K . XLA-associated neutropenia treatment: a case report and review of the literature. J Pediatr Hematol Oncol. 2008; 30(8):631-4. DOI: 10.1097/MPH.0b013e3181758947. View

15.

Kjeldsen L, Calafat J, Borregaard N . Giant granules of neutrophils in Chediak-Higashi syndrome are derived from azurophil granules but not from specific and gelatinase granules. J Leukoc Biol. 1998; 64(1):72-7. DOI: 10.1002/jlb.64.1.72. View

16.

Yanez L, Sanchez-Escamilla M, Perales M . CAR T Cell Toxicity: Current Management and Future Directions. Hemasphere. 2019; 3(2):e186. PMC: 6746032. DOI: 10.1097/HS9.0000000000000186. View

17.

Introne W, Boissy R, Gahl W . Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. Mol Genet Metab. 1999; 68(2):283-303. DOI: 10.1006/mgme.1999.2927. View

18.

Fried S, Avigdor A, Bielorai B, Meir A, Besser M, Schachter J . Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019; 54(10):1643-1650. DOI: 10.1038/s41409-019-0487-3. View

19.

Brahmer J, Lacchetti C, Thompson J . Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2018; 14(4):247-249. DOI: 10.1200/JOP.18.00005. View

20.

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View